297 results on '"Go, Alan S"'
Search Results
2. Comparative CKD risk prediction using homocitrulline and carbamylated albumin: two circulating markers of protein carbamylation.
- Author
-
Awwad, Aya, Rhee, Eugene P., Grams, Morgan, Choles, Hernan Rincon, Sondheimer, James, He, Jiang, Chen, Jing, Hsu, Chi-yuan, Vasan, Ramachandran S, Kimmel, Paul L., Wulczyn, Kendra, Berg, Anders, Lash, Jim, Tang, Mengyao, Kalim, Sahir, Anderson, Amanda H, Appel, Lawrence J., Cohen, Debbie L, Dember, Laura M, and Go, Alan S.
- Subjects
POST-translational modification ,CHRONIC kidney failure ,PROPORTIONAL hazards models ,ALBUMINS ,PEARSON correlation (Statistics) - Abstract
Background: Protein carbamylation, a post-translational protein modification primarily driven by urea, independently associates with adverse clinical outcomes in patients with CKD. Biomarkers used to quantify carbamylation burden have mainly included carbamylated albumin (C-Alb) and homocitrulline (HCit, carbamylated lysine). In this study, we aimed to compare the prognostic utility of these two markers in order to facilitate comparisons of existing studies employing either marker alone, and to inform future carbamylation studies. Methods: Both serum C-Alb and free HCit levels were assayed from the same timepoint in 1632 individuals with CKD stages 2–4 enrolled in the prospective Chronic Renal Insufficiency Cohort (CRIC) study. Adjusted Cox proportional hazard models were used to assess risks for the outcomes of death (primary) and end stage kidney disease (ESKD) using each marker. C-statistics, net reclassification improvement, and integrated discrimination improvement were used to compare the prognostic value of each marker. Results: Participant demographics included mean (SD) age 59 (11) years; 702 (43%) females; 700 (43%) white. C-Alb and HCit levels were positively correlated with one another (Pearson correlation coefficient 0.64). Higher C-Alb and HCit levels showed similar increased risk of death (e.g., the adjusted hazard ratio [HR] for death in the 4th carbamylation quartile compared to the 1st was 1.90 (95% confidence interval [CI] 1.35–2.66) for C-Alb, and 1.89 [1.27–2.81] for HCit; and on a continuous scale, the adjusted HR for death using C-Alb was 1.24 [1.11 to 1.39] per standard deviation increase, and 1.27 [1.10–1.46] using HCit). Both biomarkers also had similar HRs for ESKD. The C-statistics were similar when adding each carbamylation biomarker to base models (e.g., for mortality models, the C-statistic was 0.725 [0.707–0.743] with C-Alb and 0.725 [0.707–0.743] with HCit, both compared to a base model 0.723). Similarities were also observed for the net reclassification improvement and integrated discrimination improvement metrics. Conclusions: C-Alb and HCit had similar performance across multiple prognostic assessments. The markers appear readily comparable in CKD epidemiological studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Initial antiretroviral therapy regimen and risk of heart failure.
- Author
-
Silverberg, Michael J., Pimentel, Noel, Leyden, Wendy A., Leong, Thomas K., Reynolds, Kristi, Ambrosy, Andrew P., Towner, William J., Hechter, Rulin C., Horberg, Michael, Vupputuri, Suma, Harrison, Teresa N., Lea, Alexandra N., Sue Hee Sung, Go, Alan S., and Neugebauer, Romain
- Published
- 2024
- Full Text
- View/download PDF
4. Development and Validation of the American Heart Association’s PREVENT Equations.
- Author
-
Khan, Sadiya S., Kunihiro Matsushita, Yingying Sang, Ballew, Shoshana H., Grams, Morgan E., Surapaneni, Aditya, Blaha, Michael J., Carson, April P., Chang, Alexander R., Ciemins, Elizabeth, Go, Alan S., Gutierrez, Orlando M., Shih-Jen Hwang, Jassal, Simerjot K., Kovesdy, Csaba P., Lloyd-Jones, Donald M., Shlipak, Michael G., Palaniappan, Latha P., Sperling, Laurence, and Virani, Salim S.
- Published
- 2024
- Full Text
- View/download PDF
5. Gaps in guideline-recommended anticoagulation in patients with atrial fibrillation and elevated thromboembolic risk within an integrated healthcare delivery system.
- Author
-
Malik, Sushmita, Gustafson, Shanshan, Chang, Huai-En R., Tamrat, Yonas, Go, Alan S., and Berry, Natalia
- Subjects
ATRIAL fibrillation ,THROMBOEMBOLISM ,ANTICOAGULANTS ,BLACK white differences ,CONGESTIVE heart failure - Abstract
Background: Atrial Fibrillation (AF) is the leading cause of stroke, which can be reduced by 70% with appropriate oral anticoagulation (OAC) therapy. Nationally, appropriate anticoagulation rates for patients with AF with elevated thromboembolic risk are as low as 50% even across the highest stroke risk cohorts. This study aims to evaluate the variability of appropriate anticoagulation rates among patients by sex, ethnicity, and socioeconomic status within the Kaiser Permanente Mid-Atlantic States (KPMAS). Methods: This retrospective study investigated 9513 patients in KPMAS's AF registry with CHADS
2 score ≥ 2 over a 6-month period in 2021. Results: Appropriately anticoagulated patients had higher rates of diabetes, prior stroke, and congestive heart failure than patients who were not appropriately anticoagulated. There were no significant differences in anticoagulation rates between males and females (71.8% vs. 71.6%%, [OR] 1.01; 95% CI, 0.93-1.11; P =.76) nor by SES-SVI quartiles. There was a statistically significant difference between Black and White patients (70.8% vs. 73.1%, P =.03) and Asian and White patients (68.3% vs. 71.6%, P =.005). After adjusting for CHADS2 , this difference persisted for Black and White participants with CHADS2 scores of ≤3 (62.6% vs. 70.6%, P <.001) and for Asian and White participants with CHADS2 scores > 5 (68.0% vs. 79.3%, P <.001). Conclusions: Black and Asian patients may have differing rates of appropriate anticoagulation when compared with White patients. Characterizing such disparities is the first step towards addressing treatment gaps in AF. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
6. CKD stage-specific utility of two equations for predicting 1-year risk of ESKD.
- Author
-
Zheng, Sijie, Parikh, Rishi V., Tan, Thida C., Pravoverov, Leonid, Patel, Jignesh K., Horiuchi, Kate M., and Go, Alan S.
- Subjects
CHRONIC kidney failure ,KIDNEY failure ,RENAL replacement therapy - Abstract
Background: The Kidney Failure Risk Equation (KFRE) and Kaiser Permanente Northwest (KPNW) models have been proposed to predict progression to ESKD among adults with CKD within 2 and 5 years. We evaluated the utility of these equations to predict the 1-year risk of ESKD in a contemporary, ethnically diverse CKD population. Methods: We conducted a retrospective cohort study of adult members of Kaiser Permanente Northern California (KPNC) with CKD Stages 3–5 from January 2008-September 2015. We ascertained the onset of ESKD through September 2016, and calculated stage-specific estimates of model discrimination and calibration for the KFRE and KPNW equations. Results: We identified 108,091 eligible adults with CKD (98,757 CKD Stage 3; 8,384 CKD Stage 4; and 950 CKD Stage 5 not yet receiving kidney replacement therapy), with mean age of 75 years, 55% women, and 37% being non-white. The overall 1-year risk of ESKD was 0.8% (95%CI: 0.8–0.9%). The KFRE displayed only moderate discrimination for CKD 3 and 5 (c = 0.76) but excellent discrimination for CKD 4 (c = 0.86), with good calibration for CKD 3–4 patients but suboptimal calibration for CKD 5. Calibration by CKD stage was similar to KFRE for the KPNW equation but displayed worse calibration across CKD stages for 1-year ESKD prediction. Conclusions: In a large, ethnically diverse, community-based CKD 3–5 population, both the KFRE and KPNW equation were suboptimal in accurately predicting the 1-year risk of ESKD within CKD stage 3 and 5, but more accurate for stage 4. Our findings suggest these equations can be used in1-year prediction for CKD 4 patients, but also highlight the need for more personalized, stage-specific equations that predicted various short- and long-term adverse outcomes to better inform overall decision-making. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Proteomics of CKD progression in the chronic renal insufficiency cohort.
- Author
-
Dubin, Ruth F., Deo, Rajat, Ren, Yue, Wang, Jianqiao, Zheng, Zihe, Shou, Haochang, Go, Alan S., Parsa, Afshin, Lash, James P., Rahman, Mahboob, Hsu, Chi-yuan, Weir, Matthew R., Chen, Jing, Anderson, Amanda, Grams, Morgan E., Surapaneni, Aditya, Coresh, Josef, Li, Hongzhe, Kimmel, Paul L., and Vasan, Ramachandran S.
- Subjects
CHRONIC kidney failure ,KIDNEY failure ,PROTEOMICS ,BLOOD proteins ,METABOLIC bone disorders ,BLOOD coagulation factor X - Abstract
Progression of chronic kidney disease (CKD) portends myriad complications, including kidney failure. In this study, we analyze associations of 4638 plasma proteins among 3235 participants of the Chronic Renal Insufficiency Cohort Study with the primary outcome of 50% decline in estimated glomerular filtration rate or kidney failure over 10 years. We validate key findings in the Atherosclerosis Risk in the Communities study. We identify 100 circulating proteins that are associated with the primary outcome after multivariable adjustment, using a Bonferroni statistical threshold of significance. Individual protein associations and biological pathway analyses highlight the roles of bone morphogenetic proteins, ephrin signaling, and prothrombin activation. A 65-protein risk model for the primary outcome has excellent discrimination (C-statistic[95%CI] 0.862 [0.835, 0.889]), and 14/65 proteins are druggable targets. Potentially causal associations for five proteins, to our knowledge not previously reported, are supported by Mendelian randomization: EGFL9, LRP-11, MXRA7, IL-1 sRII and ILT-2. Modifiable protein risk markers can guide therapeutic drug development aimed at slowing CKD progression. Progression of chronic kidney disease may lead to kidney failure and cardiovascular, metabolic and bone disease complications. Here, the authors conduct a large-scale proteomic study in patients with chronic kidney disease, identify numerous proteins that predict kidney failure, some of which are likely causal mediators and hence potential therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Developing Clinical Risk Prediction Models for Worsening Heart Failure Events and Death by Left Ventricular Ejection Fraction.
- Author
-
Parikh, Rishi V., Go, Alan S., Bhatt, Ankeet S., Tan, Thida C., Allen, Amanda R., Feng, Kent Y., Hamilton, Steven A., Tai, Andrew S., Fitzpatrick, Jesse K., Lee, Keane K., Adatya, Sirtaz, Avula, Harshith R., Sax, Dana R., Xian Shen, Cristino, Joaquim, Sandhu, Alexander T., Heidenreich, Paul A., and Ambrosy, Andrew P.
- Published
- 2023
- Full Text
- View/download PDF
9. Early Pregnancy Systolic Blood Pressure Patterns Predict Early- and Later-Onset Preeclampsia and Gestational Hypertension Among Ostensibly Low-to-Moderate Risk Groups.
- Author
-
Gunderson, Erica P., Greenberg, Mara, Baiyang Sun, Goler, Nancy, Go, Alan S., Roberts, James M., Nguyen-Huynh, Mai N., Wei Tao, and Alexeeff, Stacey E.
- Published
- 2023
- Full Text
- View/download PDF
10. Early Pregnancy Systolic Blood Pressure Patterns Predict Early-and Later-Onset Preeclampsia and Gestational Hypertension Among Ostensibly Low-to-Moderate Risk Groups.
- Author
-
Gunderson, Erica P., Greenberg, Mara, Baiyang Sun, Goler, Nancy, Go, Alan S., Roberts, James M., Nguyen-Huynh, Mai N., Wei Tao, and Alexeeff, Stacey E.
- Published
- 2023
- Full Text
- View/download PDF
11. Risk for Chronic Kidney Disease Progression After Acute Kidney Injury: Findings From the Chronic Renal Insufficiency Cohort Study.
- Author
-
Muiru, Anthony N., Hsu, Jesse Y., Zhang, Xiaoming, Appel, Lawrence J., Chen, Jing, Cohen, Debbie L., Drawz, Paul E., Freedman, Barry I., Go, Alan S., He, Jiang, Horwitz, Edward J., Hsu, Raymond K., Lash, James P., Liu, Kathleen D., McCoy, Ian E., Porter, Anna, Rao, Panduranga, Ricardo, Ana C., Rincon-Choles, Hernan, and Sondheimer, James
- Subjects
CHRONIC kidney failure ,ACUTE kidney failure ,DISEASE risk factors ,DISEASE progression ,COHORT analysis - Abstract
The effect of acute kidney injury in patients with chronic kidney disease is a subject of debate. This multicenter cohort study examined 3150 patients with chronic kidney disease to determine subsequent kidney function and trajectory after hospitalizations with acute kidney injury. Visual Abstract. Risk for Chronic Kidney Disease Progression After Acute Kidney Injury: Findings From the Chronic Renal Insufficiency Cohort Study The effect of acute kidney injury in patients with chronic kidney disease is a subject of debate. This multicenter cohort study examined 3150 patients with chronic kidney disease to determine subsequent kidney function and trajectory after hospitalizations with acute kidney injury. Background: Prior studies associating acute kidney injury (AKI) with more rapid subsequent loss of kidney function had methodological limitations, including inadequate control for differences between patients who had AKI and those who did not. Objective: To determine whether AKI is independently associated with subsequent kidney function trajectory among patients with chronic kidney disease (CKD). Design: Multicenter prospective cohort study. Setting: United States. Participants: Patients with CKD (n = 3150). Measurements: Hospitalized AKI was defined by a 50% or greater increase in inpatient serum creatinine (SCr) level from nadir to peak. Kidney function trajectory was assessed using estimated glomerular filtration rate (eGFR) based on SCr level (eGFRcr) or cystatin C level (eGFRcys) measured at annual study visits. Results: During a median follow-up of 3.9 years, 433 participants had at least 1 AKI episode. Most episodes (92%) had stage 1 or 2 severity. There were decreases in eGFRcr (−2.30 [95% CI, −3.70 to −0.86] mL/min/1.73 m 2) and eGFRcys (−3.61 [CI, −6.39 to −0.82] mL/min/1.73 m 2) after AKI. However, in fully adjusted models, the decreases were attenuated to −0.38 (CI, −1.35 to 0.59) mL/min/1.73 m 2 for eGFRcr and −0.15 (CI, −2.16 to 1.86) mL/min/1.73 m 2 for eGFRcys, and the CI bounds included the possibility of no effect. Estimates of changes in eGFR slope after AKI determined by either SCr level (0.04 [CI, −0.30 to 0.38] mL/min/1.73 m 2 per year) or cystatin C level (−0.56 [CI, −1.28 to 0.17] mL/min/1.73 m 2 per year) also had CI bounds that included the possibility of no effect. Limitations: Few cases of severe AKI, no adjudication of AKI cause, and lack of information about nephrotoxic exposures after hospital discharge. Conclusion: After pre-AKI eGFR, proteinuria, and other covariables were accounted for, the association between mild to moderate AKI and worsening subsequent kidney function in patients with CKD was small. Primary Funding Source: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
- Author
-
Piazza, Gregory, Spyropoulos, Alex C., Hsia, Judith, Goldin, Mark, Towner, William J., Go, Alan S., Bull, Todd M., Weng, Stephen, Lipardi, Concetta, Barnathan, Elliot S., and Bonaca, Marc P.
- Published
- 2023
- Full Text
- View/download PDF
13. Proteomic cardiovascular risk assessment in chronic kidney disease.
- Author
-
Deo, Rajat, Dubin, Ruth F, Ren, Yue, Murthy, Ashwin C, Wang, Jianqiao, Zheng, Haotian, Zheng, Zihe, Feldman, Harold, Shou, Haochang, Coresh, Josef, Grams, Morgan, Surapaneni, Aditya L, Bhat, Zeenat, Cohen, Jordana B, Rahman, Mahboob, He, Jiang, Saraf, Santosh L, Go, Alan S, Kimmel, Paul L, and Vasan, Ramachandran S
- Subjects
CHRONIC kidney failure ,CARDIOVASCULAR diseases risk factors ,PROTEOMICS ,RECEIVER operating characteristic curves ,RISK assessment - Abstract
Aims Chronic kidney disease (CKD) is widely prevalent and independently increases cardiovascular risk. Cardiovascular risk prediction tools derived in the general population perform poorly in CKD. Through large-scale proteomics discovery, this study aimed to create more accurate cardiovascular risk models. Methods and results Elastic net regression was used to derive a proteomic risk model for incident cardiovascular risk in 2182 participants from the Chronic Renal Insufficiency Cohort. The model was then validated in 485 participants from the Atherosclerosis Risk in Communities cohort. All participants had CKD and no history of cardiovascular disease at study baseline when ∼5000 proteins were measured. The proteomic risk model, which consisted of 32 proteins, was superior to both the 2013 ACC/AHA Pooled Cohort Equation and a modified Pooled Cohort Equation that included estimated glomerular filtrate rate. The Chronic Renal Insufficiency Cohort internal validation set demonstrated annualized receiver operating characteristic area under the curve values from 1 to 10 years ranging between 0.84 and 0.89 for the protein and 0.70 and 0.73 for the clinical models. Similar findings were observed in the Atherosclerosis Risk in Communities validation cohort. For nearly half of the individual proteins independently associated with cardiovascular risk, Mendelian randomization suggested a causal link to cardiovascular events or risk factors. Pathway analyses revealed enrichment of proteins involved in immunologic function, vascular and neuronal development, and hepatic fibrosis. Conclusion In two sizeable populations with CKD, a proteomic risk model for incident cardiovascular disease surpassed clinical risk models recommended in clinical practice, even after including estimated glomerular filtration rate. New biological insights may prioritize the development of therapeutic strategies for cardiovascular risk reduction in the CKD population. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. The association between changes in echocardiography and risk of heart failure hospitalizations and death in adults with chronic kidney disease.
- Author
-
Fitzpatrick, Jesse K., Parikh, Rishi V., Hamilton, Steven A., Ambrosy, Andrew P., Tan, Thida C., Bansal, Nisha, Go, Alan S., for the CRIC Study Investigators, Appel, Lawrence J., Chen, Jing, Lash, James P., Nelson, Robert G., Rahman, Mahboob, Rao, Panduranga S., Shah, Vallabh O., Townsend, Raymond R., and Unruh, Mark L.
- Subjects
CHRONIC kidney failure ,PROPORTIONAL hazards models ,HEART failure ,ECHOCARDIOGRAPHY ,HOSPITAL care - Abstract
Adults with chronic kidney disease (CKD) are at increased risk for developing heart failure (HF). However, longitudinal cardiac remodeling in CKD has not been well-characterized and its association with HF outcomes remains unknown. We evaluated the association between change in echocardiographic parameters between baseline and year 4 with the subsequent risk of HF hospitalization and death using Cox proportional hazard models in a landmark analysis of a prospective multicenter CKD cohort. Among 2673 participants, mean ± SD age was 61 ± 11 years, with 45% women, and 56% non-white. A total of 472 hospitalizations for HF and 776 deaths occurred during a median (interquartile range) follow-up duration of 8.0 (6.3–9.1) years. Patients hospitalized for HF experienced larger preceding absolute increases in left ventricular (LV) volumes and decreases in LV ejection fraction. Adverse changes in LV ejection fraction, LV cavity volume, LV mass index, and LV geometry were independently associated with an increased risk of HF hospitalization and death. Among adults with CKD, deleterious cardiac remodeling occurs over a relatively short timeframe and adverse remodeling is associated with increased risk of HF-related morbidity and mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Health Literacy and Treatment Satisfaction Among Patients with Venous Thromboembolism.
- Author
-
Mefford, Matthew T., Zhou, Hui, Fan, Dongjie, Fang, Margaret C., Prasad, Priya A., Go, Alan S., Portugal, Cecilia, Chang, John M., and Reynolds, Kristi
- Subjects
PATIENT satisfaction ,HEALTH literacy ,THROMBOEMBOLISM ,PATIENT compliance ,SATISFACTION - Abstract
Background: Venous thromboembolism (VTE) treatment requires complex management, and patients with limited health literacy (HL) may perceive higher burden and lower benefits associated with their treatment. Objective: To examine the association of HL with treatment satisfaction among patients with VTE. Design: Retrospective cohort study Participants: Kaiser Permanente Southern and Northern California members who were taking oral anticoagulants (OAC) for incident VTE between 2015 and 2018 were surveyed. Main Measures HL was assessed using a 3-item HL assessment and dichotomized as having adequate or limited HL. High treatment burden and low treatment benefit were defined as Anti-Clot Treatment Scale (ACTS) scores below the 25th percentile of the distributions for ACTS Burdens and Benefits survey components, respectively. Using Poisson regression, multivariable adjusted risk ratios (RR) and 95% confidence intervals (CI) were calculated for the association of HL with high treatment burden and low treatment benefits. Results: Among 2154 respondents, 397 (18.4%) had limited HL. Patients with limited vs adequate HL were older (47.9% vs 27.5% aged ≥ 75 years, p<0.001), more likely to use a non-English language when discussing their health (10.8% vs 1.7%, p<0.001), to have less than high school education (10.1% vs 1.7%, p<0.001), and to self-rate their health as fair or poor (47.6% vs 25.5%, p<0.001). After multivariable adjustment, patients with limited HL were more likely to have higher perceived treatment burden (RR 1.24, 95% CI 1.07, 1.45) and lower perceived treatment benefits (RR 1.21, 95% CI 1.08, 1.37). Conclusions: Limited HL was associated with lower OAC treatment satisfaction, though absolute differences in satisfaction scores were small. Further examination of the intersection of HL with VTE treatment satisfaction and compliance among older and non-English speaking patients is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Approach to Multimorbidity Burden Classification and Outcomes in Older Adults With Heart Failure.
- Author
-
Tisminetzky, Mayra, Gurwitz, Jerry H., Tabada, Grace, Reynolds, Kristi, Smith, David H., Sung, Sue Hee, Goldberg, Robert, and Go, Alan S.
- Published
- 2023
- Full Text
- View/download PDF
17. Analytical and Biological Variability of a Commercial Modified Aptamer Assay in Plasma Samples of Patients with Chronic Kidney Disease.
- Author
-
Dubin, Ruth F, Deo, Rajat, Ren, Yue, Lee, Hongzhe, Shou, Haochang, Feldman, Harold, Kimmel, Paul, Waikar, Sushrut S, Rhee, Eugene P, Tin, Adrienne, Chen, Jingsha, Coresh, Joseph, Go, Alan S, Kelly, Tanika, Rao, Paduranga S, Chen, Teresa K, Segal, Mark R, and Ganz, Peter
- Subjects
CHRONIC kidney failure ,TUMOR necrosis factor receptors ,APTAMERS ,CHRONICALLY ill ,SYSTEMIC lupus erythematosus - Abstract
Background: We carried out a study of the aptamer proteomic assay, SomaScan V4, to evaluate the analytical and biological variability of the assay in plasma samples of patients with moderate to severe chronic kidney disease (CKD). Methods: Plasma samples were selected from 2 sources: (a) 24 participants from the Chronic Renal Insufficiency Cohort (CRIC) and (b) 49 patients from the Brigham and Women's Hospital–Kidney/Renal Clinic. We calculated intra-assay variability from both sources and examined short-term biological variability in samples from the Brigham clinic. We also measured correlations of aptamer measurements with traditional biomarker assays. Results: A total of 4656 unique proteins (4849 total aptamer measures) were analyzed in all samples. Median (interquartile range [IQR] intra-assay CV) was 3.7% (2.8–5.3) in CRIC and 5.0% (3.8–7.0) in Brigham samples. Median (IQR) biological CV among Brigham samples drawn from one individual on 2 occasions separated by median (IQR) 7 (4–14) days was 8.7% (6.2–14). CVs were independent of CKD stage, diabetes, or albuminuria but were higher in patients with systemic lupus erythematosus. Rho correlations between aptamer and traditional assays for biomarkers of interest were cystatin C = 0.942, kidney injury model-1 = 0.905, fibroblast growth factor-23 = 0.541, tumor necrosis factor receptors 1 = 0.781 and 2 = 0.843, P < 10
−100 for all. Conclusions: Intra-assay and within-subject variability for SomaScan in the CKD setting was low and similar to assay variability reported from individuals without CKD. Intra-assay precision was excellent whether samples were collected in an optimal research protocol, as were CRIC samples, or in the clinical setting, as were the Brigham samples. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
18. Incident Atrial Fibrillation and Risk of Dementia in a Diverse, Community-Based Population.
- Author
-
Bansal, Nisha, Zelnick, Leila R., Jaejin An, Harrison, Teresa N., Ming-Sum Lee, Singer, Daniel E., Dongjie Fan, and Go, Alan S.
- Published
- 2023
- Full Text
- View/download PDF
19. Breast arterial calcification is associated with incident atrial fibrillation among older but not younger post-menopausal women.
- Author
-
Iribarren, Carlos, Chandra, Malini, Parikh, Rishi V, Sanchez, Gabriela, Sam, Danny L, Azamian, Farima Faith, Cho, Hyo-Min, Ding, Huanjun, Molloi, Sabee, and Go, Alan S
- Subjects
CALCIFICATIONS of the breast ,ARTERIAL calcification ,ATRIAL fibrillation ,POSTMENOPAUSE ,YOUNG women ,ATRIAL flutter - Abstract
Aims The goal of this study was to examine the association of breast arterial calcification (BAC) presence and quantity with incident atrial fibrillation (AF) in a large cohort of post-menopausal women. Methods and results We conducted a longitudinal cohort study among women free of clinically overt cardiovascular disease and AF at baseline (between October 2012 and February 2015) when they attended mammography screening. Atrial fibrillation incidence was ascertained using diagnostic codes and natural language processing. Among 4908 women, 354 incident cases of AF (7%) were ascertained after a mean (standard deviation) of 7 (2) years of follow-up. In Cox regression adjusting for a propensity score for BAC, BAC presence vs. absence was not significantly associated with AF [hazard ratio (HR) = 1.12; 95% confidence interval (CI), 0.89–1.42; P = 0.34]. However, a significant (a priori hypothesized) age by BAC interaction was found (P = 0.02) such that BAC presence was not associated with incident AF in women aged 60–69 years (HR = 0.83; 95% CI, 0.63–1.15; P = 0.26) but was significantly associated with incident AF in women aged 70–79 years (HR = 1.75; 95% CI, 1.21–2.53; P = 0.003). No evidence of dose–response relationship between BAC gradation and AF was noted in the entire cohort or in age groups separately. Conclusion Our results demonstrate, for the first time, an independent association between BAC and AF in women over age 70 years. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
20. Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop.
- Author
-
Go, Alan S., Al-Khatib, Sana M., Desvigne-Nickens, Patrice, Bansal, Nisha, Bushnell, Cheryl D., Fang, Margaret C., Freeman, James V., Gage, Brian F., Hanke, Thorsten, Hylek, Elaine M., Lopes, Renato D., Noseworthy, Peter A., Reddy, Vivek Y., Singer, Daniel E., Thomas, Kevin L., True Hills, Mellanie, Turakhia, Mintu P., Zieman, Susan J., Cooper, Lawton S., and Benjamin, Emelia J.
- Published
- 2023
- Full Text
- View/download PDF
21. Transforming Atrial Fibrillation Research to Integrate Social Determinants of Health: A National Heart, Lung, and Blood Institute Workshop Report.
- Author
-
Benjamin, Emelia J., Thomas, Kevin L., Go, Alan S., Desvigne-Nickens, Patrice, Albert, Christine M., Alonso, Alvaro, Chamberlain, Alanna M., Essien, Utibe R., Hernandez, Inmaculada, Hills, Mellanie True, Kershaw, Kiarri N., Levy, Phillip D., Magnani, Jared W., Matlock, Daniel D., O'Brien, Emily C., Rodriguez, Carlos J., Russo, Andrea M., Soliman, Elsayed Z., Cooper, Lawton S., and Al-Khatib, Sana M.
- Published
- 2023
- Full Text
- View/download PDF
22. Predicting Cardiovascular Events after Sepsis with Death as a Competing Risk.
- Author
-
Myers, Laura C., Knox, Daniel, Thai, Khanh K., Kipnis, Patricia, Jacobs, Jason, Lee, Catherine, Desai, Manisha, Devis, Ycar, Clancy, Heather, Lu, Yun W., Go, Alan S., Liu, Vincent X., and Walkey, Allan J.
- Published
- 2023
- Full Text
- View/download PDF
23. Performance of the pooled cohort equation in South Asians: insights from a large integrated healthcare delivery system.
- Author
-
Mantri, Neha M., Merchant, Maqdooda, Rana, Jamal S., Go, Alan S., and Pursnani, Seema K.
- Subjects
SOUTH Asians ,STATINS (Cardiovascular agents) ,ISCHEMIC stroke ,MYOCARDIAL infarction ,CARDIOVASCULAR disease related mortality - Abstract
South Asian ethnicity is associated with increased atherosclerotic cardiovascular disease (ASCVD) risk and has been identified as a "risk enhancer" in the 2018 American College of Cardiology/American Heart Association Guidelines. Risk estimation and statin eligibility in South Asians is not well understood; we studied the accuracy of 10-years ASCVD risk prediction by the pooled cohort equation (PCE), based on statin use, in a South Asian cohort. This is a retrospective cohort study of Kaiser Permanente Northern California South Asian members without existing ASCVD, age range 30–70, and 10-years follow up. ASCVD events were defined as myocardial infarction, ischemic stroke, and cardiovascular death. The cohort was stratified by statin use during the study period: never; at baseline and during follow-up; and only during follow-up. Predicted probability of ASCVD, using the PCE was calculated and compared to observed ASCVD events for low < 5.0%, borderline 5.0 to < 7.5%, intermediate 7.5 to < 20.0%, and high ≥ 20.0% risk groups. A total of 1835 South Asian members were included: 773 never on statin, 374 on statins at baseline and follow-up, and 688 on statins during follow-up only. ASCVD risk was underestimated by the PCE in low-risk groups: entire cohort: 1.8 versus 4.9%, p < 0.0001; on statin at baseline and follow-up: 2.58 versus 8.43%, p < 0.0001; on statin during follow-up only: 2.18 versus 7.77%, p < 0.0001; and never on statin: 1.37 versus 2.09%, p = 0.12. In this South Asian cohort, the PCE underestimated risk in South Asians, regardless of statin use, in the low risk ASCVD risk category. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. The anticoagulation length of therapy and risk of new adverse events in venous thromboembolism (ALTERNATIVE) study: Design and survey results.
- Author
-
Portugal, Cecilia, Fang, Margaret C., Go, Alan S., Zhou, Hui, Chang, John, Prasad, Priya, Fan, Dongjie, Garcia, Elisha A., Sung, Sue Hee, and Reynolds, Kristi
- Subjects
ETHNICITY ,TREATMENT duration ,THROMBOEMBOLISM ,INTEGRATED health care delivery ,PATIENT satisfaction ,QUALITY of life - Abstract
The Anticoagulation Length of Therapy and Risk of New Adverse Events In Venous Thromboembolism (ALTERNATIVE) study was designed to compare the benefits and harms of different treatment options for extended treatment of venous thromboembolism (VTE). In this paper, we describe the study cohort, survey data collection, and preliminary results. We identified 39,605 adult patients (age ≥ 18 years) from two large integrated health care delivery systems who were diagnosed with incident VTE and received initial anticoagulation therapy of 3 months or longer. A subset of the cohort (12,737) was invited to participate in a survey. Surveys were completed in English, Spanish or Mandarin via a mailed questionnaire, an online secure web link, or telephone. The survey domains included demographics, personal medical history, anticoagulant treatment history, anticoagulant treatment satisfaction, health-related quality of life and health literacy. A total of 5,017 patients participated in the survey for an overall response rate of 39.4%. The mean (SD) age of the survey respondents was 63.0 (14.5) years and self-reported race was 76.0% White/European, 11.1% Black/African American, and 3.8% Asian/Pacific Islander and 14.0% reported Hispanic ethnicity. Sixty percent of respondents completed the web survey, while 29.0% completed the mail-in paper survey, and 11.0% completed the survey via telephone. The ALTERNATIVE Study will address knowledge gaps by comparing several treatment alternatives for the extended management of VTE so that this information could be used by patients and clinicians to make more informed, patient-centered treatment choices. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Absence of long-term changes in urine biomarkers after AKI: findings from the CRIC study.
- Author
-
McCoy, Ian E., Hsu, Jesse Y., Bonventre, Joseph V., Parikh, Chirag R., Go, Alan S., Liu, Kathleen D., Ricardo, Ana C., Srivastava, Anand, Cohen, Debbie L., He, Jiang, Chen, Jing, Rao, Panduranga S., Muiru, Anthony N., and Hsu, Chi-yuan
- Subjects
CHRONIC kidney failure ,URINE ,BIOMARKERS - Abstract
Background: Mechanisms by which AKI leads to CKD progression remain unclear. Several urine biomarkers have been identified as independent predictors of progressive CKD. It is unknown whether AKI may result in long-term changes in these urine biomarkers, which may mediate the effect of AKI on CKD progression. Methods: We selected 198 episodes of hospitalized AKI (defined as peak/nadir inpatient serum creatinine values ≥ 1.5) among adult participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. We matched the best non-AKI hospitalization (unique patients) for each AKI hospitalization using pre-hospitalization characteristics including eGFR and urine protein/creatinine ratio. Biomarkers were measured in banked urine samples collected at annual CRIC study visits. Results: Urine biomarker measurements occurred a median of 7 months before and 5 months after hospitalization. There were no significant differences in the change in urine biomarker-to-creatinine ratio between the AKI and non-AKI groups: KIM-1/Cr + 9% vs + 7%, MCP-1/Cr + 4% vs + 1%, YKL-40/Cr + 7% vs -20%, EGF/Cr -11% vs -8%, UMOD/Cr -2% vs -7% and albumin/Cr + 17% vs + 13% (all p > 0.05). Conclusion: In this cohort of adults with CKD, AKI did not associate with long-term changes in urine biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. The race coefficient in glomerular filtration rate-estimating equations and its removal.
- Author
-
Hsu, Chi-yuan and Go, Alan S.
- Published
- 2022
- Full Text
- View/download PDF
27. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding.
- Author
-
Go, Alan S., Leong, Thomas K., Sung, Sue Hee, Wei, Rong, Harrison, Teresa N., Gupta, Nigel, Baker, Nicole, Goldstein, Brahm, Ataher, Quazi, Solomon, Matthew D., and Reynolds, Kristi
- Abstract
Limited data exist in large, representative populations about whether the risk of thromboembolic events varies after receiving four-factor human prothrombin complex concentrate (4F-PCC) versus treatment with human plasma for urgent reversal of oral vitamin K antagonist therapy. We conducted a multicenter observational study to compare the 45-day risk of thromboembolic events in adults with warfarin-associated major bleeding after treatment with 4F-PCC (Kcentra®) or plasma. Hospitalized patients in two large integrated healthcare delivery systems who received 4F-PCC or plasma for reversal of warfarin due to major bleeding from January 1, 2008 to March 31, 2020 were identified and were matched 1:1 on potential confounders and a high-dimensional propensity score. Arterial and venous thromboembolic events were identified up to 45 days after receiving 4F-PCC or plasma from electronic health records and adjudicated by physician review. Among 1119 patients receiving 4F-PCC and a matched historical cohort of 1119 patients receiving plasma without a recent history of thromboembolism, mean (SD) age was 76.7 (10.5) years, 45.6% were women, and 9.4% Black, 14.6% Asian/Pacific Islander, and 15.7% Hispanic. The 45-day risk of thromboembolic events was 3.4% in those receiving 4F-PCC and 4.1% in those receiving plasma (P = 0.26; adjusted hazard ratio 0.76; 95% confidence interval 0.49–1.16). The adjusted risk of all-cause death at 45 days post-treatment was lower in those receiving 4F-PCC compared with plasma. Among a large, ethnically diverse cohort of adults treated for reversal of warfarin-associated bleeding, receipt of 4F-PCC was not associated with an excess risk of thromboembolic events at 45 days compared with plasma therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Variation in Heart Failure Risk by HIV Severity and Sex in People With HIV Infection.
- Author
-
Lam, Jennifer O., Leyden, Wendy A., Leong, Thomas K., Horberg, Michael A., Reynolds, Kristi, Ambrosy, Andrew P., Avula, Harshith R., Hechter, Rulin C., Towner, William J., Vupputuri, Suma, Go, Alan S., and Silverberg, Michael J.
- Published
- 2022
- Full Text
- View/download PDF
29. Effect of Medically Tailored Meals on Clinical Outcomes in Recently Hospitalized High-Risk Adults.
- Author
-
Go, Alan S., Tan, Thida C., Horiuchi, Kate M., Laws, Denise, Ambrosy, Andrew P., Lee, Keane K., Maring, Benjamin L., Joy, Jena, Couch, Cathryn, Hepfer, Paul, Lo, Joan C., Parikh, Rishi V., and KP NOURISH Study Investigators
- Published
- 2022
- Full Text
- View/download PDF
30. Absence of long-term changes in urine biomarkers after AKI: findings from the CRIC study.
- Author
-
McCoy, Ian E., Hsu, Jesse Y., Bonventre, Joseph V., Parikh, Chirag R., Go, Alan S., Liu, Kathleen D., Ricardo, Ana C., Srivastava, Anand, Cohen, Debbie L., He, Jiang, Chen, Jing, Rao, Panduranga S., Muiru, Anthony N., and Hsu, Chi-yuan
- Abstract
Background: Mechanisms by which AKI leads to CKD progression remain unclear. Several urine biomarkers have been identified as independent predictors of progressive CKD. It is unknown whether AKI may result in long-term changes in these urine biomarkers, which may mediate the effect of AKI on CKD progression.Methods: We selected 198 episodes of hospitalized AKI (defined as peak/nadir inpatient serum creatinine values ≥ 1.5) among adult participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. We matched the best non-AKI hospitalization (unique patients) for each AKI hospitalization using pre-hospitalization characteristics including eGFR and urine protein/creatinine ratio. Biomarkers were measured in banked urine samples collected at annual CRIC study visits.Results: Urine biomarker measurements occurred a median of 7 months before and 5 months after hospitalization. There were no significant differences in the change in urine biomarker-to-creatinine ratio between the AKI and non-AKI groups: KIM-1/Cr + 9% vs + 7%, MCP-1/Cr + 4% vs + 1%, YKL-40/Cr + 7% vs -20%, EGF/Cr -11% vs -8%, UMOD/Cr -2% vs -7% and albumin/Cr + 17% vs + 13% (all p > 0.05).Conclusion: In this cohort of adults with CKD, AKI did not associate with long-term changes in urine biomarkers. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
31. Vitamin K Status and Cognitive Function in Adults with Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort.
- Author
-
Shea, M Kyla, Wang, Jifan, Barger, Kathryn, Weiner, Daniel E, Booth, Sarah L, Seliger, Stephen L, Anderson, Amanda H, Deo, Rajat, Feldman, Harold I, Go, Alan S, He, Jiang, Ricardo, Ana C, Tamura, Manjula Kurella, and Investigators, The Cric Study
- Subjects
VITAMIN K ,CHRONIC kidney failure ,COGNITIVE ability ,KIDNEY diseases ,EXTRACELLULAR matrix proteins - Abstract
Vitamin K is linked to cognitive function, but studies in individuals with chronic kidney disease (CKD), who are at risk for vitamin K insufficiency and cognitive impairment, are lacking. The cross-sectional association of vitamin K status biomarkers with cognitive performance was evaluated in ≥55-y-old adults with CKD (N = 714, 49% female, 44% black). A composite score of a cognitive performance test battery, calculated by averaging the z scores of the individual tests, was the primary outcome. Vitamin K status was measured using plasma phylloquinone and dephospho-uncarboxylated matrix Gla protein [(dp)ucMGP]. Participants with low plasma (dp)ucMGP, reflecting higher vitamin K status, had better cognitive performance than those in the two higher (dp)ucMGP categories based on the composite outcome (P = 0.03), whereas it did not significantly differ according to plasma phylloquinone categories (P = 0.08). Neither biomarker was significantly associated with performance on individual tests (all P > 0.05). The importance of vitamin K to cognitive performance in adults with CKD remains to be clarified. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
32. Association of Estimated GFR Calculated Using Race-Free Equations With Kidney Failure and Mortality by Black vs Non-Black Race.
- Author
-
Gutiérrez, Orlando M., Sang, Yingying, Grams, Morgan E., Ballew, Shoshana H., Surapaneni, Aditya, Matsushita, Kunihiro, Go, Alan S., Shlipak, Michael G., Inker, Lesley A., Eneanya, Nwamaka D., Crews, Deidra C., Powe, Neil R., Levey, Andrew S., and Coresh, Josef
- Subjects
CHRONIC kidney failure ,PROTEINS ,GLOMERULAR filtration rate ,RESEARCH ,RESEARCH methodology ,RETROSPECTIVE studies ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,CREATININE - Abstract
Importance: At a given estimated glomerular filtration rate (eGFR), individuals who are Black have higher rates of mortality and kidney failure with replacement therapy (KFRT) compared with those who are non-Black. Whether the recently adopted eGFR equations without race preserve racial differences in risk of mortality and KFRT at a given eGFR is unknown.Objective: To assess whether eGFR equations with and without race and cystatin C document racial differences in risk of KFRT and mortality in populations including Black and non-Black participants.Design, Setting, and Participants: Retrospective individual-level data analysis of 62 011 participants from 5 general population and 3 chronic kidney disease (CKD) US-based cohorts with serum creatinine, cystatin C, and follow-up for KFRT and mortality from 1988 to 2018.Exposures: Chronic Kidney Disease Epidemiology Collaboration equation with serum creatinine (eGFRcr with and without race), cystatin C (eGFRcys without race), or both markers (eGFRcr-cys without race).Main Outcomes and Measures: The prevalence of decreased eGFR at baseline and hazard ratios of KFRT and mortality in Black vs non-Black participants were calculated, adjusted for age and sex. Analyses were performed within each cohort and with random-effect meta-analyses of the models.Results: Among 62 011 participants (20 773 Black and 41 238 non-Black; mean age, 63 years; 53% women), the prevalence ratio (95% CI; percent prevalences) of eGFR less than 60 mL/min/1.73 m2 comparing Black with non-Black participants was 0.98 (95% CI, 0.93-1.03; 11% vs 12%) for eGFRcr with race, 0.95 (95% CI, 0.91-0.98; 17% vs 18%) for eGFRcys, and 1.2 (95% CI, 1.2-1.3; 13% vs 11%) for eGFRcr-cys but was 1.8 (95% CI, 1.7-1.8; 15% vs 9%) for eGFRcr without race. During a mean follow-up of 13 years, 8% and 4% of Black and non-Black participants experienced KFRT and 34% and 39% died, respectively. Decreased eGFR was associated with significantly greater risk of both outcomes for all equations. At an eGFR of 60 mL/min/1.73 m2, the hazard ratios for KFRT comparing Black with non-Black participants were 2.8 (95% CI, 1.6-4.9) for eGFRcr with race, 3.0 (95% CI, 1.5-5.8) for eGFRcys, and 2.8 (95% CI, 1.4-5.4) for eGFRcr-cys vs 1.3 (95% CI, 0.8-2.1) for eGFRcr without race. The 5-year absolute risk differences for KFRT comparing Black with non-Black participants were 1.4% (95% CI, 0.2%-2.6%) for eGFRcr with race, 1.1% (95% CI, 0.2%-1.9%) for eGFRcys, and 1.3% (95% CI, 0%-2.6%) for eGFRcr-cys vs 0.37% (95% CI, -0.32% to 1.05%) for eGFRcr without race. Similar patterns were observed for mortality.Conclusions and Relevance: In this retrospective analysis of 8 US cohorts including Black and non-Black individuals, the eGFR equation without race that included creatinine and cystatin C, but not the eGFR equation without race that included creatinine without cystatin C, demonstrated racial differences in the risk of KFRT and mortality throughout the range of eGFR. The eGFRcr-cys equation may be preferable to the eGFRcr equation without race for assessing racial differences in the risk of KFRT and mortality associated with low eGFR. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
33. Prediction of End-Stage Kidney Disease Using Estimated Glomerular Filtration Rate With and Without Race : A Prospective Cohort Study.
- Author
-
Bundy, Joshua D., Mills, Katherine T., Anderson, Amanda H., Yang, Wei, Chen, Jing, He, Jiang, Appel, Lawrence J., Feldman, Harold I., Go, Alan S., Lash, James P., Nelson, Robert G., Rahman, Mahboob, Rao, Panduranga S., Shah, Vallabh O., Townsend, Raymond R., Unruh, Mark L., and CRIC Study Investigators*
- Subjects
CHRONIC kidney failure ,GLOMERULAR filtration rate ,LONGITUDINAL method ,DISEASE risk factors ,KIDNEY failure ,CHRONIC kidney failure complications ,KIDNEY function tests ,RESEARCH funding ,CREATININE - Abstract
Background: New estimated glomerular filtration rate (eGFR) equations removed race adjustment, but the impact of its removal on prediction of end-stage kidney disease (ESKD) is unknown.Objective: To compare the ESKD prediction performance of different eGFR equations.Design: Observational, prospective cohort study.Setting: 7 U.S. clinical centers.Participants: 3873 participants with chronic kidney disease (CKD) from the CRIC (Chronic Renal Insufficiency Cohort) Study contributing 13 902 two-year risk periods.Measurements: ESKD was defined as initiation of dialysis or transplantation. eGFR was calculated using 5 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations based on serum creatinine and/or cystatin C, with or without race adjustment. The predicted 2-year risk for ESKD was calculated using the 4-variable Kidney Failure Risk Equation (KFRE). We evaluated the prediction performance of eGFR equations and the KFRE score using discrimination and calibration analyses.Results: During a maximum 16 years of follow-up, 856 participants developed ESKD. Across all eGFR equations, the KFRE score was superior for predicting 2-year incidence of ESKD compared with eGFR alone (area under the curve ranges, 0.945 to 0.954 vs. 0.900 to 0.927). Prediction performance of KFRE scores using different eGFR equations was similar, but the creatinine equation without race adjustment improved calibration among Black participants. Among all participants, compared with an eGFR less than 20 mL/min/1.73 m2, a KFRE score greater than 20% had similar specificity for predicting 2-year ESKD risk (ranges, 0.94 to 0.97 vs. 0.95 to 0.98) but higher sensitivity (ranges, 0.68 to 0.78 vs. 0.42 to 0.66).Limitation: Data are solely from the United States.Conclusion: The KFRE score better predicts 2-year risk for ESKD compared with eGFR alone, regardless of race adjustment. The creatinine equation with age and sex may improve calibration among Black patients. A KFRE score greater than 20% showed high specificity and sensitivity for predicting 2-year risk for ESKD.Primary Funding Source: National Institutes of Health. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
34. Early Pregnancy Blood Pressure Patterns Identify Risk of Hypertensive Disorders of Pregnancy Among Racial and Ethnic Groups.
- Author
-
Gunderson, Erica P., Greenberg, Mara, Nguyen-Huynh, Mai N., Tierney, Cassidy, Roberts, James M., Go, Alan S., Tao, Wei, and Alexeeff, Stacey E.
- Published
- 2022
- Full Text
- View/download PDF
35. Food security, diet quality, nutritional knowledge, and attitudes towards research in adults with heart failure during the COVID‐19 pandemic.
- Author
-
Ambrosy, Andrew P., Malik, Umar I., Leong, Thomas K., Allen, Amanda R., Sung, Sue Hee, and Go, Alan S.
- Subjects
COVID-19 pandemic ,VEGETARIANS ,FOOD security ,HEART failure ,COVID-19 ,ADULTS ,CARDIAC research - Abstract
Background: The impact of the novel coronavirus disease 2019 (COVID‐19) pandemic on diet and nutrition among older adults with chronic medical conditions have not been well‐described. Methods: We conducted a survey addressing (1) food access, (2) diet quality and composition, (3) nutritional understanding, and (4) attitudes towards research among adults with heart failure (HF) within an integrated health system. Adults (≥18 years) with diagnosed HF and at least one prior hospitalization for HF within the last 12 months were approached to complete the survey electronically or by mail. Outcomes included all‐cause and HF‐specific hospitalizations and all‐cause death was ascertained via the electronic health record. Results: Among 1212 survey respondents (32.5% of eligible patients) between May 18, 2020 and September 30, 2020, mean ± SD age was 77.9 ± 11.4 years, 50.1% were women, and median (25th–75th) left ventricular ejection fraction was 55% (40%–60%). Overall, 15.1% of respondents were food insecure, and only 65% of participants answered correctly more than half of the items assessing nutritional knowledge. Although most respondents were willing to participate in future research, that number largely declined for studies requiring blood draws (32.2%), study medication (14.4%), and/or behavior change (27.1%). Food security, diet quality, and nutritional knowledge were not independently associated with outcomes at 90 or 180 days. Conclusion: In a cohort of older adults with HF and multiple comorbidities, a significant proportion reported issues with food access, diet quality, and nutritional knowledge during the COVID‐19 pandemic. Future research should evaluate interventions targeting these domains in at‐risk individuals. Key points: Upwards of 15% of respondents screened positive for food insecurity, and only approximately 65% of respondents answered more than half of the items correctly on a questionnaire assessing nutritional understanding.Although the majority of respondents indicated that would be willing to consider participating in future research, that proportion declined markedly for studies requiring blood draws, study drugs, and/or behavior change.None of the functional domains assessed by this survey were independently associated with clinical outcomes in our cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. Dialysis therapy and mortality in older adults with heart failure and advanced chronic kidney disease: A high-dimensional propensity-matched cohort study.
- Author
-
Zheng, Sijie, Yang, Jingrong, Tan, Thida C., Belani, Sharina, Law, David, Pravoverov, Leonid V., Kim, Susan S., and Go, Alan S.
- Subjects
CHRONIC kidney failure ,OLDER people ,DEATH rate ,DIALYSIS (Chemistry) ,HEART failure ,OLDER patients ,HEART assist devices ,HEART disease related mortality - Abstract
Background: Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, and the combination is linked to poor outcomes, but limited data exist to guide optimal management. We evaluated the outcome of dialysis therapy in older patients with HF and advanced CKD. Methods: We examined adults aged ≥70 years with HF and eGFR ≤20 ml/min/1.73 m
2 between 2008–2012 and no prior renal replacement therapy, cancer, cirrhosis or organ transplant. We identified patients who initiated chronic dialysis through 2013 and matched patients who did not initiate dialysis on age, gender, diabetes status, being alive on dialysis initiation date, and a high-dimensional propensity score for starting dialysis. Deaths were identified through 2013. We used Cox regression to evaluate the association of chronic dialysis and all-cause death. Results: Among 348 adults with HF and advanced CKD who initiated dialysis and 947 matched patients who did not start dialysis, mean age was 80±5 years, 51% were women and 33% were Black. The crude rate of death was high overall but lower in those initiating vs. not initiating chronic dialysis (26.1 vs. 32.1 per 100 person-years, respectively, P = 0.02). In multivariable analysis, dialysis was associated with a 33% (95% Confidence Interval:17–46%) lower adjusted rate of death compared with not initiating dialysis. Conclusions: Among older adults with HF and advanced CKD, dialysis initiation was associated with lower mortality, but absolute rates of death were very high in both groups. Randomized trials should evaluate net outcomes of dialysis vs. conservative management on length and quality of life in this high-risk population. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
37. Change in ankle–brachial index and mortality among individuals with chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort Study.
- Author
-
Dorans, Kirsten S, He, Hua, Chen, Jing, Dobre, Mirela, Go, Alan S, Hamm, L Lee, Jaar, Bernard G, Mehta, Rupal C, Rahman, Mahboob, Ricardo, Ana C, Rosas, Sylvia E, Srivastava, Anand, He, Jiang, and Investigators, the CRIC Study
- Subjects
CHRONIC kidney failure ,ANKLE brachial index ,LEG amputation ,COHORT analysis ,PERIPHERAL vascular diseases - Abstract
Background Patients with chronic kidney disease (CKD) have an increased risk of peripheral arterial disease (PAD). The ankle–brachial index (ABI), a noninvasive measure of PAD, is a predictor of adverse events among individuals with CKD. In general populations, changes in ABI have been associated with mortality, but this association is not well understood among patients with CKD. Methods We conducted a prospective study of 2920 participants in the Chronic Renal Insufficiency Cohort Study without lower extremity revascularization or amputation at baseline and with at least one follow-up ABI measurement (taken at annual visits) during the first 4 years of follow-up. The ABI was obtained by the standard protocol. Results In Cox proportional hazard regression analyses, we found a U-shaped association of average annual change in ABI with all-cause mortality. After adjusting for baseline ABI and other covariates, compared with participants with an average annual change in ABI of 0–<0.02, individuals with an average annual change in ABI <−0.04 or ≥0.04 had multivariable-adjusted hazard ratios (HRs) of 1.81 [95% confidence interval (CI) 1.34–2.44) and 1.42 (95% CI 1.12–1.82) for all-cause mortality, respectively. Compared with the cumulative average ABI of 1.0–<1.4, multivariable-adjusted HRs for those with a cumulative average ABI of <0.9, 0.9–<1.0 and ≥1.4 were 1.93 (95% CI 1.42–2.61), 1.20 (0.90–1.62) and 1.31 (0.94–1.82), respectively. Conclusions This study indicates both larger decreases and increases in average annual changes in ABI (>0.04/year) were associated with higher mortality risk. Monitoring changes in ABI over time may facilitate risk stratification for mortality among individuals with CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensin‐converting enzyme inhibitor therapy.
- Author
-
Mansi, Elizabeth T., Johnson, Eric S., Thorp, Micah L., Go, Alan S., Lee, Ming‐Sum, Shen, Albert Yuh‐Jer, Park, Ken J., Budzynska, Katarzyna, Markin, Abraham, Sung, Sue Hee, Thompson, Jamie H., Slaughter, Matthew T., Luong, Tiffany Q., An, Jaejin, Reynolds, Kristi, Roblin, Douglas W., Cassidy‐Bushrow, Andrea E., Kuntz, Jennifer L., Schlienger, Raymond G., and Behr, Sigrid
- Abstract
Purpose: Our objective was to calculate the positive predictive value (PPV) of the ICD‐9 diagnosis code for angioedema when physicians adjudicate the events by electronic health record review. Our secondary objective was to evaluate the inter‐rater reliability of physician adjudication. Methods: Patients from the Cardiovascular Research Network previously diagnosed with heart failure who were started on angiotensin‐converting enzyme inhibitors (ACEI) during the study period (July 1, 2006 through September 30, 2015) were included. A team of two physicians per participating site adjudicated possible events using electronic health records for all patients coded for angioedema for a total of five sites. The PPV was calculated as the number of physician‐adjudicated cases divided by all cases with the diagnosis code of angioedema (ICD‐9‐CM code 995.1) meeting the inclusion criteria. The inter‐rater reliability of physician teams, or kappa statistic, was also calculated. Results: There were 38 061 adults with heart failure initiating ACEI in the study (21 489 patient‐years). Of 114 coded events that were adjudicated by physicians, 98 angioedema events were confirmed for a PPV of 86% (95% CI: 80%, 92%). The kappa statistic based on physician inter‐rater reliability was 0.65 (95% CI: 0.47, 0.82). Conclusions: ICD‐9 diagnosis code of 995.1 (angioneurotic edema, not elsewhere classified) is highly predictive of angioedema in adults with heart failure exposed to ACEI. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care.
- Author
-
Olender, Susan A, Perez, Katherine K, Go, Alan S, Balani, Bindu, Price-Haywood, Eboni G, Shah, Nirav S, Wang, Su, Walunas, Theresa L, Swaminathan, Shobha, Slim, Jihad, Chin, BumSik, Wit, Stéphane De, Ali, Shamim M, Viladomiu, Alex Soriano, Robinson, Philip, Gottlieb, Robert L, Tsang, Tak Yin Owen, Lee, I-Heng, Hu, Hao, and Haubrich, Richard H
- Subjects
DRUG efficacy ,COVID-19 ,CONFIDENCE intervals ,MULTIPLE regression analysis ,ANTIVIRAL agents ,RETROSPECTIVE studies ,OXYGEN saturation ,TREATMENT effectiveness ,COMPARATIVE studies ,ODDS ratio - Abstract
Background We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and a retrospective cohort of patients with severe COVID-19 treated with standard of care. Methods GS-US-540–5773 is an ongoing phase 3, randomized, open-label trial comparing two courses of remdesivir (remdesivir-cohort). GS-US-540–5807 is an ongoing real-world, retrospective cohort study of clinical outcomes in patients receiving standard-of-care treatment (non-remdesivir-cohort). Inclusion criteria were similar between studies: patients had confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, were hospitalized, had oxygen saturation ≤94% on room air or required supplemental oxygen, and had pulmonary infiltrates. Stabilized inverse probability of treatment weighted multivariable logistic regression was used to estimate the treatment effect of remdesivir versus standard of care. The primary endpoint was the proportion of patients with recovery on day 14, dichotomized from a 7-point clinical status ordinal scale. A key secondary endpoint was mortality. Results After the inverse probability of treatment weighting procedure, 312 and 818 patients were counted in the remdesivir- and non-remdesivir-cohorts, respectively. At day 14, 74.4% of patients in the remdesivir-cohort had recovered versus 59.0% in the non-remdesivir-cohort (adjusted odds ratio [aOR] 2.03: 95% confidence interval [CI]: 1.34–3.08, P <.001). At day 14, 7.6% of patients in the remdesivir-cohort had died versus 12.5% in the non-remdesivir-cohort (aOR 0.38, 95% CI:.22–.68, P =.001). Conclusions In this comparative analysis, by day 14, remdesivir was associated with significantly greater recovery and 62% reduced odds of death versus standard-of-care treatment in patients with severe COVID-19. Clinical Trials Registration NCT04292899 and EUPAS34303. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism.
- Author
-
Fang, Margaret C., Go, Alan S., Prasad, Priya A., Hsu, Jin-Wen, Fan, Dongjie, Portugal, Cecilia, Sung, Sue Hee, and Reynolds, Kristi
- Abstract
Treatment options for patients with venous thromboembolism (VTE) include warfarin and direct oral anticoagulants (DOACs). Although DOACs are easier to administer than warfarin and do not require routine laboratory monitoring, few studies have directly assessed whether patients are more satisfied with DOACs. We surveyed adults from two large integrated health systems taking DOACs or warfarin for incident VTE occurring between January 1, 2015 and June 30, 2018. Treatment satisfaction was assessed using the validated Anti-Clot Treatment Scale (ACTS), divided into the ACTS Burdens and ACTS Benefits scores; higher scores indicate greater satisfaction. Mean treatment satisfaction was compared using multivariable linear regression, adjusting for patient demographic and clinical characteristics. The effect size of the difference in means was calculated using a Cohen's d (0.20 is considered a small effect and ≥ 0.80 is considered large). We surveyed 2217 patients, 969 taking DOACs and 1248 taking warfarin at the time of survey. Thirty-one point five percent of the cohort was aged ≥ 75 years and 43.1% were women. DOAC users were on average more satisfied with anticoagulant treatment, with higher adjusted mean ACTS Burdens (50.18 v. 48.01, p < 0.0001) and ACTS Benefits scores (10.21 v. 9.84, p = 0.046) for DOACs vs. warfarin, respectively. The magnitude of the difference was small (Cohen's d of 0.29 for ACTS Burdens and 0.12 for ACTS Benefits). Patients taking DOACs for venous thromboembolism were on average more satisfied with anticoagulant treatment than were warfarin users, although the magnitude of the difference was small. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Population-based identification and temporal trend of children with primary nephrotic syndrome: The Kaiser Permanente nephrotic syndrome study.
- Author
-
Parikh, Rishi V., Tan, Thida C., Fan, Dongjie, Law, David, Salyer, Anne S., Yankulin, Leonid, Wojcicki, Janet M., Zheng, Sijie, Ordonez, Juan D., Chertow, Glenn M., Khoshniat-Rad, Farzien, Yang, Jingrong, and Go, Alan S.
- Subjects
NEPHROTIC syndrome ,FOCAL segmental glomerulosclerosis ,ELECTRONIC health records ,CLINICAL pathology ,MEDICAL records - Abstract
Introduction: Limited population-based data exist about children with primary nephrotic syndrome (NS). Methods: We identified a cohort of children with primary NS receiving care in Kaiser Permanente Northern California, an integrated healthcare delivery system caring for >750,000 children. We identified all children <18 years between 1996 and 2012 who had nephrotic range proteinuria (urine ACR>3500 mg/g, urine PCR>3.5 mg/mg, 24-hour urine protein>3500 mg or urine dipstick>300 mg/dL) in laboratory databases or a diagnosis of NS in electronic health records. Nephrologists reviewed health records for clinical presentation and laboratory and biopsy results to confirm primary NS. Results: Among 365 cases of confirmed NS, 179 had confirmed primary NS attributed to presumed minimal change disease (MCD) (72%), focal segmental glomerulosclerosis (FSGS) (23%) or membranous nephropathy (MN) (5%). The overall incidence of primary NS was 1.47 (95% Confidence Interval:1.27–1.70) per 100,000 person-years. Biopsy data were available in 40% of cases. Median age for patients with primary NS was 6.9 (interquartile range:3.7 to 12.9) years, 43% were female and 26% were white, 13% black, 17% Asian/Pacific Islander, and 32% Hispanic. Conclusion: This population-based identification of children with primary NS leveraging electronic health records can provide a unique approach and platform for describing the natural history of NS and identifying determinants of outcomes in children with primary NS. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. COVID-19 and Risk of VTE in Ethnically Diverse Populations.
- Author
-
Go, Alan S., Reynolds, Kristi, Tabada, Grace H., Prasad, Priya A., Sung, Sue Hee, Garcia, Elisha, Portugal, Cecilia, Fan, Dongjie, Pai, Ashok P., and Fang, Margaret C.
- Abstract
Background: Limited existing data suggest that the novel COVID-19 may increase risk of VTE, but information from large, ethnically diverse populations with appropriate control participants is lacking.Research Question: Does the rate of VTE among adults hospitalized with COVID-19 differ from matched hospitalized control participants without COVID-19?Study Design and Methods: We conducted a retrospective study among hospitalized adults with laboratory-confirmed COVID-19 and hospitalized adults without evidence of COVID-19 matched for age, sex, race or ethnicity, acute illness severity, and month of hospitalization between February 2020 and August 2020 from two integrated health-care delivery systems with 36 hospitals. Outcomes included VTE (DVT or pulmonary embolism ascertained using diagnosis codes combined with validated natural language processing algorithms applied to electronic health records) and death resulting from any cause at 30 days. Fine and Gray hazards regression was performed to evaluate the association of COVID-19 with VTE after accounting for competing risk of death and residual differences between groups, as well as to identify predictors of VTE in patients with COVID-19.Results: We identified 6,319 adults with COVID-19 and 6,319 matched adults without COVID-19, with mean ± SD age of 60.0 ± 17.2 years, 46% women, 53.1% Hispanic, 14.6% Asian/Pacific Islander, and 10.3% Black. During 30-day follow-up, 313 validated cases of VTE (160 COVID-19, 153 control participants) and 1,172 deaths (817 in patients with COVID-19, 355 in control participants) occurred. Adults with COVID-19 showed a more than threefold adjusted risk of VTE (adjusted hazard ratio, 3.48; 95% CI, 2.03-5.98) compared with matched control participants. Predictors of VTE in patients with COVID-19 included age ≥ 55 years, Black race, prior VTE, diagnosed sepsis, prior moderate or severe liver disease, BMI ≥ 40 kg/m2, and platelet count > 217 k/μL.Interpretation: Among ethnically diverse hospitalized adults, COVID-19 infection increased the risk of VTE, and selected patient characteristics were associated with higher thromboembolic risk in the setting of COVID-19. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
43. Timing of AKI after urgent percutaneous coronary intervention and clinical outcomes: a high-dimensional propensity score analysis.
- Author
-
Go, Alan S., Tan, Thida C., Parikh, Rishi V., Ambrosy, Andrew P., Pravoverov, Leonid V., Zheng, Sijie, and Leong, Thomas K.
- Subjects
PERCUTANEOUS coronary intervention ,KIDNEY transplantation ,ACUTE kidney failure ,TREATMENT effectiveness ,CHRONIC kidney failure ,PROPORTIONAL hazards models - Abstract
Introduction: Acute kidney injury is a common complication of percutaneous coronary intervention and has been associated with an increased risk of death and progressive chronic kidney disease. However, whether the timing of acute kidney injury after urgent percutaneous coronary intervention could be used to improve patient risk stratification is not known.Methods: We conducted a retrospective cohort study in adults surviving an urgent percutaneous coronary intervention between 2008 and 2013 within Kaiser Permanente Northern California, a large integrated healthcare delivery system, to evaluate the impact of acute kidney injury during hospitalization at 12 (±6), 24 (±6) and 48 (±6) hours after urgent percutaneous coronary intervention and subsequent risks of adverse outcomes within the first year after discharge. We used multivariable Cox proportional hazards models with adjustment for a high-dimensional propensity score for developing acute kidney injury after percutaneous coronary intervention to examine the associations between acute kidney injury timing and all-cause death and worsening chronic kidney disease.Results: Among 7250 eligible adults undergoing urgent percutaneous coronary intervention, 306 (4.2%) had acute kidney injury at one or more of the examined time periods after percutaneous coronary intervention. After adjustment, acute kidney injury at 12 (±6) hours was independently associated with higher risks of death (adjusted hazard ratio [aHR] 3.55, 95% confidence interval [CI] 2.19-5.75) and worsening kidney function (aHR 2.40, 95% CI:1.24-4.63). Similar results were observed for acute kidney injury at 24 (±6) hours and death (aHR 3.90, 95% CI:2.29-6.66) and worsening chronic kidney disease (aHR 4.77, 95% CI:2.46-9.23). Acute kidney injury at 48 (±6) hours was associated with excess mortality (aHR 1.97, 95% CI:1.19-3.26) but was not significantly associated with worsening kidney function (aHR 0.91, 95% CI:0.42-1.98).Conclusions: Timing of acute kidney injury after urgent percutaneous coronary intervention may be differentially associated with subsequent risk of worsening kidney function but not death. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
44. Association between Troponin I Levels during Sepsis and Postsepsis Cardiovascular Complications.
- Author
-
Garcia, Michael A., Rucci, Justin M., Thai, Khanh K., Yun Lu, Kipnis, Patricia, Go, Alan S., Desai, Manisha, Bosch, Nicholas A., Martinez, Adriana, Clancy, Heather, Devis, Ycar, Myers, Laura C., Liu, Vincent X., and Walkey, Allan J.
- Subjects
TROPONIN ,RESEARCH ,TIME ,RESEARCH methodology ,RETROSPECTIVE studies ,MEDICAL cooperation ,EVALUATION research ,SEPSIS ,RISK assessment ,COMPARATIVE studies ,RESEARCH funding ,HEART diseases ,LONGITUDINAL method ,DISEASE complications - Abstract
Rationale: Sepsis commonly results in elevated serum troponin levels and increased risk for postsepsis cardiovascular complications; however, the association between troponin levels during sepsis and cardiovascular complications after sepsis is unclear.Objectives: To evaluate the association between serum troponin levels during sepsis and 1 year after sepsis cardiovascular events.Methods: We analyzed adults aged ⩾40 years without preexisting cardiovascular disease within 5 years, admitted with sepsis across 21 hospitals from 2011 to 2017. Peak serum troponin I levels during sepsis were grouped as normal (⩽0.04 ng/ml) or tertiles of abnormal (>0.04 to ⩽0.09 ng/ml, >0.09 to ⩽0.42 ng/ml, or >0.42 ng/ml). Multivariable adjusted cause-specific Cox proportional hazards models with death as a competing risk were used to assess associations between peak troponin I levels and a composite cardiovascular outcome (atherosclerotic cardiovascular disease, atrial fibrillation, and heart failure) in the year following sepsis. Models were adjusted for presepsis and intrasepsis factors considered potential confounders.Measurements and Main Results: Among 14,046 eligible adults with troponin I measured, 2,012 (14.3%) experienced the composite cardiovascular outcome, including 832 (10.9%) patients with normal troponin levels, as compared with 370 (17.3%), 376 (17.6%), and 434 (20.3%) patients within each sequential abnormal troponin tertile, respectively (P < 0.001). Patients within the elevated troponin tertiles had increased risks of adverse cardiovascular events (adjusted hazard ratio [aHR]troponin0.04-0.09 = 1.37; 95% confidence interval [CI], 1.20-1.55; aHRtroponin0.09-0.42 = 1.44; 95% CI, 1.27-1.63; and aHRtroponin>0.42 = 1.77; 95% CI, 1.56-2.00).Conclusions: Among patients without preexisting cardiovascular disease, troponin elevation during sepsis identified patients at increased risk for postsepsis cardiovascular complications. Strategies to mitigate cardiovascular complications among this high-risk subset of patients are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
45. Risk of atherosclerotic cardiovascular disease by cardiovascular health metric categories in approximately 1 million patients.
- Author
-
Rana, Jamal S., Liu, Jennifer Y., Moffet, Howard H., Karter, Andrew J., Nasir, Khurram, Solomon, Matthew D., Jaffe, Marc G., Ambrosy, Andrew P., Go, Alan S., and Sidney, Stephen
- Published
- 2021
- Full Text
- View/download PDF
46. Achieved blood pressure post-acute kidney injury and risk of adverse outcomes after AKI: A prospective parallel cohort study.
- Author
-
McCoy, Ian, Brar, Sandeep, Liu, Kathleen D., Go, Alan S., Hsu, Raymond K., Chinchilli, Vernon M., Coca, Steven G., Garg, Amit X., Himmelfarb, Jonathan, Ikizler, T. Alp, Kaufman, James, Kimmel, Paul L., Lewis, Julie B., Parikh, Chirag R., Siew, Edward D., Ware, Lorraine B., Zeng, Hui, Hsu, Chi-yuan, and Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study investigators
- Subjects
BLOOD pressure ,SYSTOLIC blood pressure ,HYPERTENSION ,HEART failure ,KIDNEY injuries - Abstract
Background: There has recently been considerable interest in better understanding how blood pressure should be managed after an episode of hospitalized AKI, but there are scant data regarding the associations between blood pressure measured after AKI and subsequent adverse outcomes. We hypothesized that among AKI survivors, higher blood pressure measured three months after hospital discharge would be associated with worse outcomes. We also hypothesized these associations between blood pressure and outcomes would be similar among those who survived non-AKI hospitalizations.Methods: We quantified how systolic blood pressure (SBP) observed three months after hospital discharge was associated with risks of subsequent hospitalized AKI, loss of kidney function, mortality, and heart failure events among 769 patients in the prospective ASSESS-AKI cohort study who had hospitalized AKI. We repeated this analysis among the 769 matched non-AKI ASSESS-AKI enrollees. We then formally tested for AKI interaction in the full cohort of 1538 patients to determine if these associations differed among those who did and did not experience AKI during the index hospitalization.Results: Among 769 patients with AKI, 42 % had subsequent AKI, 13 % had loss of kidney function, 27 % died, and 18 % had heart failure events. SBP 3 months post-hospitalization did not have a stepwise association with the risk of subsequent AKI, loss of kidney function, mortality, or heart failure events. Among the 769 without AKI, there was also no stepwise association with these risks. In formal interaction testing using the full cohort of 1538 patients, hospitalized AKI did not modify the association between post-discharge SBP and subsequent risks of adverse clinical outcomes.Conclusions: Contrary to our first hypothesis, we did not observe that higher stepwise blood pressure measured three months after hospital discharge with AKI was associated with worse outcomes. Our data were consistent with our second hypothesis that the association between blood pressure measured three months after hospital discharge and outcomes among AKI survivors is similar to that observed among those who survived non-AKI hospitalizations. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
47. Association of tubular solute clearances with the glomerular filtration rate and complications of chronic kidney disease: the Chronic Renal Insufficiency Cohort study.
- Author
-
Chen, Yan, Zelnick, Leila R, Wang, Ke, Katz, Ronit, Hoofnagle, Andrew N, Becker, Jessica O, Hsu, Chi-Yuan, Go, Alan S, Feldman, Harold I, Mehta, Rupal C, Lash, James P, Waikar, Sushrut S, Hamm, L, Chen, Jing, Shafi, Tariq, Kestenbaum, Bryan R, and Investigators, the CRIC Study
- Subjects
CHRONIC kidney failure ,GLOMERULAR filtration rate ,KIDNEY diseases ,KIDNEY physiology ,COHORT analysis ,KIDNEY transplantation ,MOSQUITO nets - Abstract
Background The secretion of organic solutes by the proximal tubules is an essential intrinsic kidney function. The degree to which secretory solute clearance corresponds with the glomerular filtration rate (GFR) and potential metabolic implications of net secretory clearance are largely unknown. Methods We evaluated 1240 participants with chronic kidney disease (CKD) from the multicenter Chronic Renal Insufficiency Cohort (CRIC) Study. We used targeted mass-spectrometry to quantify candidate secretory solutes in paired 24-h urine and plasma samples. CRIC study personnel measured GFR using
125 I-iothalamate clearance (iGFR). We used correlation and linear regression to determine cross-sectional associations of secretory clearances with iGFR and common metabolic complications of CKD. Results Correlations between iGFR and secretory solute clearances ranged from ρ = +0.30 for hippurate to ρ = +0.58 for kynurenic acid. Lower net clearances of most secretory solutes were associated with higher serum concentrations of parathyroid hormone (PTH), triglycerides and uric acid. Each 50% lower kynurenic acid clearance was associated with a 21% higher serum PTH concentration [95% confidence interval (CI) 15–26%] and a 10% higher serum triglyceride concentration (95% CI 5–16%) after adjustment for iGFR, albuminuria and other potential confounders. Secretory solute clearances were not associated with statistically or clinically meaningful differences in serum calcium, phosphate, hemoglobin or bicarbonate concentrations. Conclusions Tubular secretory clearances are modestly correlated with measured GFR among adult patients with CKD. Lower net secretory clearances are associated with selected metabolic complications independent of GFR and albuminuria, suggesting potential clinical and biological relevance. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
48. COPD Comorbidity Profiles and 2-Year Trajectory of Acute and Postacute Care Use.
- Author
-
Shen, Ernest, Lee, Janet S., Mularski, Richard A., Crawford, Phillip, Go, Alan S., Sung, Sue H., Tabada, Grace H., Gould, Michael K., and Nguyen, Huong Q.
- Subjects
INTEGRATED health care delivery ,COMORBIDITY ,OBSTRUCTIVE lung diseases ,MEDICAL care use ,ELECTRONIC health records ,OBSTRUCTIVE lung disease treatment ,RESEARCH ,TERMINAL care ,TIME ,RESEARCH methodology ,RETROSPECTIVE studies ,MEDICAL cooperation ,EVALUATION research ,SUBACUTE care ,COMPARATIVE studies ,QUESTIONNAIRES ,LONGITUDINAL method - Abstract
Background: Multiple morbidity is the norm in advanced COPD and contributes to high symptom burden and worse outcomes.Research Question: Can distinct comorbidity profiles be identified and validated in a community-based sample of patients with COPD from a large integrated health care system using a standard, commonly used diagnostic code-based comorbidity index and downstream 2-year health care use data?Study Design and Methods: In this retrospective cohort study, we used latent class analysis (LCA) to identify comorbidity profiles in a population-based sample of 91,453 patients with a COPD diagnosis between 2011 and 2015. We included specific comorbid conditions from the Charlson Comorbidity Index (CCI) and accounted for variation in underlying prevalence of different comorbidities across the three study sites. Sociodemographic, clinical, and health-care use data were obtained from electronic health records (EHRs). Multivariate logistic regression analysis was used to compare rates of acute and postacute care use by class.Results: The mean age was 71 ± 11 years, 55% of patients were women, 23% of patients were people of color, and 80% of patients were former or current smokers. LCA identified four distinct comorbidity profiles with progressively higher CCI scores: low morbidity (61%; 1.9 ± 1.4), metabolic renal (21%; 4.7 ± 1.8), cardiovascular (12%; 4.6 ± 1.9), and multimorbidity (7%; 7.5 ± 1.7). In multivariate models, during 2 years of follow-up, a significant, nonoverlapping increase was found in the odds of having any all-cause acute (hospitalizations, observation stays, and ED visits) and postacute care use across the comorbidity profiles.Interpretation: Distinct comorbidity profiles can be identified in patients with COPD using standard EHR-based diagnostic codes, and these profiles are associated with subsequent acute and postacute care use. Population-based risk stratification schemes for end-to-end, comprehensive COPD management should consider integrating comorbidity profiles such as those found in this study. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
49. Cardiovascular disease history and β-blocker prescription patterns among Japanese and American patients with CKD: a cross-sectional study of the CRIC and CKD-JAC studies.
- Author
-
Imaizumi, Takahiro, Hamano, Takayuki, Fujii, Naohiko, Huang, Jing, Xie, Dawei, Ricardo, Ana C., He, Jiang, Soliman, Elsayed Z., Kusek, John W., Nessel, Lisa, Yang, Wei, Maruyama, Shoichi, Fukagawa, Masafumi, Feldman, Harold I., the CRIC Study Investigators, Appel, Lawrence J., Go, Alan S., Lash, James P., Nelson, Robert G., and Rahman, Mahboob
- Published
- 2021
- Full Text
- View/download PDF
50. Body mass index and chronic kidney disease outcomes after acute kidney injury: a prospective matched cohort study.
- Author
-
MacLaughlin, Helen L., Pike, Mindy, Selby, Nicholas M., Siew, Edward, Chinchilli, Vernon M., Guide, Andrew, Stewart, Thomas G., Himmelfarb, Jonathan, Go, Alan S., Parikh, Chirag R., Ghahramani, Nasrollah, Kaufman, James, Ikizler, T. Alp, Robinson-Cohen, Cassianne, for the ASSESS-AKI Study Investigators, Kaufman, James S., Kimmel, Paul L., Stokes, John B., Coca, Steven, and Garg, Amit
- Subjects
ACUTE kidney failure ,CHRONIC kidney failure ,BODY mass index ,CARDIOVASCULAR diseases ,PROPORTIONAL hazards models ,OBESITY complications ,DISEASE progression ,RESEARCH ,RESEARCH methodology ,EVALUATION research ,COMPARATIVE studies ,LONGITUDINAL method ,DISEASE complications - Abstract
Background: Acute kidney injury (AKI) and obesity are independent risk factors for chronic kidney disease (CKD). This study aimed to determine if obesity modifies risk for CKD outcomes after AKI.Methods: This prospective multisite cohort study followed adult survivors after hospitalization, with or without AKI. The primary outcome was a combined CKD event of incident CKD, progression of CKD and kidney failure, examined using time-to-event Cox proportional hazards models, adjusted for diabetes status, age, pre-existing CKD, cardiovascular disease status and intensive care unit admission, and stratified by study center. Body mass index (BMI) was added as an interaction term to examine effect modification by body size.Results: The cohort included 769 participants with AKI and 769 matched controls. After median follow-up of 4.3 years, among AKI survivors, the rate of the combined CKD outcome was 84.7 per1000-person-years with BMI ≥30 kg/m2, 56.4 per 1000-person-years with BMI 25-29.9 kg/m2, and 72.6 per 1000-person-years with BMI 20-24.9 kg/m2. AKI was associated with a higher risk of combined CKD outcomes; adjusted-HR 2.43 (95%CI 1.87-3.16), with no evidence that this was modified by BMI (p for interaction = 0.3). After adjustment for competing risk of death, AKI remained associated with a higher risk of the combined CKD outcome (subdistribution-HR 2.27, 95%CI 1.76-2.92) and similarly, there was no detectable effect of BMI modifying this risk.Conclusions: In this post-hospitalization cohort, we found no evidence for obesity modifying the association between AKI and development or progression of CKD. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.